Yu Xinyuan, Chen Weiwei, Zhang Jinjie, Gao Xinfu, Cui Qidi, Song Zheng, Du Jing, Lv Wenwen
Binzhou Medical University Hospital, Binzhou, Shandong, China.
Naunyn Schmiedebergs Arch Pharmacol. 2023 Jun;396(6):1095-1103. doi: 10.1007/s00210-023-02386-9. Epub 2023 Jan 16.
Cucurbitacin B (CuB) is a class of tetracyclic triterpenoids isolated from Cucurbitaceae with a wide range of anti-inflammatory and anti-tumor activities, mainly used in hepatitis and hepatocellular carcinoma, while there is relatively little research and application of this drug for lung cancer. In this study, CuB was administered on A549/DDP cells to observe how it affected the cells and their mechanism of action. CuB demonstrated good anti-tumor activity against A549/DDP cells in a dose-dependent manner and caused changes in the hedgehog (Hh) pathway. The results showed that CuB greatly inhibits the proliferation and the invasion of A549/DDP cells, and promoted apoptosis of A549/DDP cells. Meanwhile, it changed the expression of p53-related genes at the RNA and protein level. In conclusion, this experiment provides a theoretical basis for new applications of CuB and new thoughts on the mechanism of its anti-tumor activity, and provides a direction for deep research.
葫芦素B(CuB)是一类从葫芦科植物中分离出的四环三萜类化合物,具有广泛的抗炎和抗肿瘤活性,主要用于治疗肝炎和肝细胞癌,而该药物在肺癌方面的研究和应用相对较少。在本研究中,将CuB作用于A549/DDP细胞,以观察其对细胞的影响及其作用机制。CuB对A549/DDP细胞表现出良好的剂量依赖性抗肿瘤活性,并引起刺猬(Hh)信号通路的变化。结果表明,CuB能显著抑制A549/DDP细胞的增殖和侵袭,并促进A549/DDP细胞凋亡。同时,它在RNA和蛋白质水平上改变了p53相关基因的表达。总之,本实验为CuB的新应用及其抗肿瘤活性机制提供了理论依据和新思路,为深入研究提供了方向。